Cullinan Therapeutics’ Post

Dive into Poolbeg Pharma's vision! #POLB001 is not just a treatment; it's a growth catalyst in the battle against Cytokine Release Syndrome post-immuno-oncology. Exploring vast markets and partnerships while navigating big pharma's tides. Insightful analysis here: https://lnkd.in/ectVBvmc #BiotechGrowth #HealthcareInnovation

Common Sense Oncology will be at this year's American Society of Clinical Oncology (ASCO) annual meeting in Chicago! Join us to explore what truly matters to cancer patients, including the balance between science, commercial interests, and the hype around oncology advances. We'll dive into crucial topics such as new drugs, pharmaceutical companies, patient priorities, and the significance of value-based care. Looking forward to insightful discussions with Bishal Gyawali , Queen's University , Tim Hanna Richard Sullivan Susie Stanway,Nazik Hammad,Brian Shkabari,Fidel Rubagumya ,M.D, MMed, MPH, PhD (c) , VERNA VANDERPUYE Dr. Fabio Ynoe de Moraes See you there! #ASCO #Oncology #CancerCare #Science #PatientPriorities #ChicagoMeeting

Cutting edge opportunity here.

In my view, the importance of the below cannot be emphasized enough. Take a look at the guide for yourself (it's only 2 pages)! #oncologytrials #oncologyresearch #ecoa

🔊 Latest article! 💊Patient-centred oncology: transforming drug development As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution. Click here to read more! 👉 https://bit.ly/3WRG70z #oncology #drugdevelopment #therapeutics

Struggling to navigate FDA's Project FrontRunner for oncology drug development? Learn how to align your strategies with Project FrontRunner and accelerate the approval process ⏩ Our experts provide valuable insights to help you overcome the complexities and make informed decisions. 💻Watch our webinar now and gain a competitive edge in the evolving landscape of oncology drug development 📩 https://bit.ly/3w3xyGL #FDA #ProjectFrontRunner #Oncology

Catalyst is Project Optimus ready, are you? Read more to discover how Catalyst Oncology has seen Project Optimus play out over the past year in study designs and Phase I operations. https://lnkd.in/gwunfdkP   #ConnectWithCatalyst #AACR #ProjectOptimus #OncologyDrugDevelopment

ASCO 2024 has revealed a game-changing shift in oncology treatments. Traditional aggressive treatments are being challenged by new evidence favoring less invasive approaches, promising better patient outcomes and quality of life. How will this impact your communication strategies? Commetric's latest ASCO 2024 Media Insights Report uncovers the new narrative of "doing less to achieve more" in cancer care. Discover key media trends and the most influential companies that are shaping this transformation. Follow the link in the comments below to download the report 👇 American Society of Clinical Oncology (ASCO), GSK, Takeda, Mainz Biomed, AstraZeneca, Medicenna Therapeutics Corp., Merck, Pfizer #oncology #pharma #healthcarePR

Join us at #BIO2024 for a compelling session that delves into the heart of biopharma deals: "Is Oncology Still a Hot Spot for Biopharma Deals?" 📅 Date: Thursday, June 6, 2024 🕥 Time: 10:15 – 11:15 a.m. Oncology has long been the frontrunner in biopharma investments, with a staggering 37% of the clinical-stage drug pipeline dedicated to cancer treatments. But when it comes to M&A, the landscape is shifting. What does this mean for the industry? Our session will analyze industry data to compare oncology vs. non-oncology companies in the context of M&A and Alliances and gain our experts' opinions on where things are headed. Ben Hickey, Ross Aarons, Camille Landis, Christopher Mortko

Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/AxSS30sEs8l #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery